Neuropeptide S vs BI 456906
Head-to-head comparison of Neuropeptide S (Neuropeptide S) and BI 456906 (BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Neuropeptide S | BI 456906 |
|---|---|---|
| Category | Cognitive Enhancement | Weight Management |
| Full Name | Neuropeptide S | BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | 2203 Da | N/A |
| Half-Life | Minutes to <1 hour | Approximately 1 week |
| Amino Acids | 20 | N/A |
| Typical Dose | Research-only; no validated human dose | Trial-dependent; weekly SC dosing |
| Route | Intracerebroventricular/Intranasal | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 28 | 10 |
| Research Status | Pre-clinical | Clinical |
Neuropeptide S Benefits
- ✓anxiolysis
- ✓stress resilience
- ✓attention support
- ✓arousal modulation
BI 456906 Benefits
- ✓weight reduction
- ✓improved glucose control
- ✓lower liver-fat burden
- ✓enhanced satiety
Neuropeptide S Dosing
0.1-1 nmol i.c.v. in animal studies|intranasal research-only exploration|no established human protocol
BI 456906 Dosing
once-weekly subcutaneous injection|stepwise titration|ongoing maintenance phase
Neuropeptide S Side Effects
- ⚠sleep disruption
- ⚠headache
- ⚠jitteriness
BI 456906 Side Effects
- ⚠nausea
- ⚠abdominal discomfort
- ⚠diarrhea
Research Overview
Neuropeptide S
Animal studies suggest NPS can reduce anxiety-like behavior while altering wakefulness and alertness through the NPS receptor system. Human cognitive data are very limited, and it has no approved clinical indication.
BI 456906
Preclinical and early clinical research support meaningful metabolic effects with a tolerable safety profile. It remains investigational and is not commercially available.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.